Burning Rock Biotech (BNR) Cash from Operations (2019 - 2026)

Burning Rock Biotech's Cash from Operations history runs 8 years deep, the most recent figure standing at 4248000.0 for Q1 2026.

• In Q1 2026, Cash from Operations fell 31.25% year-over-year to 4248000.0; the TTM figure through Mar 2026 stood at 15422993.96 (up 58.93% YoY), while the FY2025 annual figure was 4068000.0, up 67.82% from the prior year.
• Cash from Operations for Q1 2026 stood at 4248000.0, down from 4002993.96 in the prior quarter.
• The five-year high for Cash from Operations was 2303000.0 in Q3 2025, with the low at 22772000.0 in Q1 2022.
• The 5-year median for Cash from Operations is 9475000.0 (2025), against an average of 9549970.86.
• The sharpest annual moves came in 2024 and 2025: Cash from Operations tumbled 468.89% in 2024, then soared 114.52% in 2025.
• Burning Rock Biotech's Cash from Operations stood at 9519880.29 in 2022, then surged by 76.3% to 2256000.0 in 2023, then sank by 468.89% to 12834112.98 in 2024, then soared by 68.81% to 4002993.96 in 2025, then fell by 6.12% to 4248000.0 in 2026.
• Business Quant data shows BNR's Cash from Operations at 4248000.0 in Q1 2026, 4002993.96 in Q4 2025, and 2303000.0 in Q3 2025.